SIP
FBIO icon

Stoneridge Investment Partners’s Fortress Biotech FBIO Stock Holding History

Stoneridge Investment Partners’s Portfolio FBIO Stock Details FBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-1,876
Closed -$74K – 211
2013
Q4 		$74K Sell
1,876
-6
-0.3% -$232 0.01% 202
2013
Q3 		$198K Buy
1,882
+413
+28% +$50.6K 0.04% 183
2013
Q2 		$190K Buy
+1,469
New +$217K 0.04% 171

Other funds holding FBIO

Elliott Management
Elliott Management New York $11.8B AUM 20.29% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Nantahala Capital Management
Nantahala Capital Management New Canaan, Connecticut $3.01B AUM 119.46% 1-Year Est. Return
BlackRock Fund Advisors
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
Royce & Associates
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
BlackRock Institutional Trust
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
Advent Capital Management
Advent Capital Management New York $4.46B AUM 0.73% 1-Year Est. Return

Stoneridge Investment Partners's FBIO Position: Q1 2014 in Review

Stoneridge Investment Partners sold out of Fortress Biotech (FBIO) in Q1 2014, closing a stake of 1,876 shares — an estimated $74K sold.

Stoneridge Investment Partners first reported a position in FBIO in Q2 2013 and held it in 3 quarters. The position peaked at $198K in Q3 2013. 57 funds tracked by Wall St. Rank hold FBIO as of Q1 2014.

  • Stoneridge Investment Partners reported no remaining Fortress Biotech position as of Q1 2014 after selling out during the quarter.
  • Stoneridge Investment Partners sold 1,876 Fortress Biotech shares in Q1 2014, an estimated $74K.
  • Stoneridge Investment Partners first reported a position in Fortress Biotech in Q2 2013 and held it in 3 quarters.
  • Stoneridge Investment Partners's Fortress Biotech position peaked at $198K in Q3 2013.
  • 57 funds tracked by Wall St. Rank held Fortress Biotech as of Q1 2014.

Based on Stoneridge Investment Partners's 13F filing for Q1 2014, filed 15 Apr 2014.